uniQure Dips on New Risk Disclosure
Research - It was just 5 days ago that Bristol-Myers Squibb (BMY) partnered with uniQure (QURE) on the discovery and development of novel gene therapies for cardiovascular … Continue Reading
Read nowSearch Results for uniqure
uniQure Fills in the Missing Piece with Bristol-Myers Collaboration
Research - Great news for our suggested uniQure (QURE) position – Bristol-Myers Squibb (BMY) is putting up $100 million upfront to partner with the European gene therapy developer … Continue Reading
Premium
Baxter’s Recent Gene Therapy Data: An Underappreciated Derisking Event for uniQure
Research - UniQure went through some interesting de-risking two weeks back with the release of initial data (the first publicly) from Baxter International’s (BAX) Hemophilia B gene therapy program, … Continue Reading
Read nowUniQure: A Dark Horse in the Gene Therapy Field
Research - We see uniQure (QURE) as a dark horse in gene therapy, in-part because of numerous catalysts in 2015 that will put fresh eyes on this European company.
Read now
ASH 2016 Updates And Takeaways
Insights - CAR-T candidates are again stealing the spotlight at ASH this year, though for entirely different reasons than in the past. First, Juno’s (JUNO) safety issues … Continue Reading
Premium
The August ‘Healthcare Huddle’ Webinar is Here
zPremium - Thursday afternoon was our latest Healthcare Huddle webinar. We covered ongoing ideas, but focused afterwards on a slew of CNS-focused companies that are worth looking … Continue Reading
Premium
ASCO Has Wrapped and EHA Is Underway
Research - ASCO has wrapped up and EHA is underway this weekend in Copenhagen. Lets take a quick look at the state of the markets as biotech … Continue Reading
Premium